AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Regeneron Pharmaceuticals Inc
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S6PX49
805.02▼ 14.07 (-1.72%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
819.09
Day's Range
801.22 – 819.09
52-Week Range
572.75 – 859.34
Volume
525.6K
Avg Volume
714.0K
Share Statistics
Shares Outstanding
Employees
15.4K
Exchange
XNAS
Listed
1991-04-02
Share count as of July 23, 2026

Regeneron Pharmaceuticals Inc (REGN) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Regeneron Pharmaceuticals Inc (REGN)
What is Regeneron Pharmaceuticals Inc's Market Cap?
Regeneron Pharmaceuticals Inc's Market Cap is $82.9B, based on as-reported figures from SEC (XBRL) filings.
What is Regeneron Pharmaceuticals Inc's Enterprise Value?
Regeneron Pharmaceuticals Inc's Enterprise Value is $77.6B, based on as-reported figures from SEC (XBRL) filings.
What is Regeneron Pharmaceuticals Inc's Trailing P/E?
Regeneron Pharmaceuticals Inc's Trailing P/E is 19.1×, based on as-reported figures from SEC (XBRL) filings.
What is Regeneron Pharmaceuticals Inc's Price / Sales?
Regeneron Pharmaceuticals Inc's Price / Sales is 5.3×, based on as-reported figures from SEC (XBRL) filings.
What is Regeneron Pharmaceuticals Inc's EV / Revenue?
Regeneron Pharmaceuticals Inc's EV / Revenue is 5.0×, based on as-reported figures from SEC (XBRL) filings.
What is Regeneron Pharmaceuticals Inc's EV / EBITDA?
Regeneron Pharmaceuticals Inc's EV / EBITDA is 17.7×, based on as-reported figures from SEC (XBRL) filings.
What is Regeneron Pharmaceuticals Inc's Revenue (TTM)?
Regeneron Pharmaceuticals Inc's Revenue (TTM) is $15.5B, based on as-reported figures from SEC (XBRL) filings.
What is Regeneron Pharmaceuticals Inc's Net Income (TTM)?
Regeneron Pharmaceuticals Inc's Net Income (TTM) is $4.3B, based on as-reported figures from SEC (XBRL) filings.
What is Regeneron Pharmaceuticals Inc's EBITDA?
Regeneron Pharmaceuticals Inc's EBITDA is $4.4B, based on as-reported figures from SEC (XBRL) filings.
What is Regeneron Pharmaceuticals Inc's Diluted EPS (TTM)?
Regeneron Pharmaceuticals Inc's Diluted EPS (TTM) is 42.04, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · REGNAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Revenues—
YoY growth+16.7%—+2.5%+0.9%
Expenses:
Research and development—
Acquired in-process research and development—
Selling, general, and administrative—
Total Expenses—
% of revenue69.9%—77.3%72.7%
Income from operations—
% of revenue30.1%—22.7%27.3%
Other income (expense):
Other income (expense), net—
Interest expense—
Total other income (expense)—
Income before income taxes—
Income tax expense—
Net income
% of revenue30.2%—21.7%38.9%
Net income per share - basic (in dollars per share)—
Net income per share - diluted (in dollars per share)—